Quick Answer
Whitehawk Therapeutics, Inc. reported Operating Income Loss of -$114.40 million for the year ending 2025.
- Whitehawk Therapeutics, Inc. showed a decrease of -69.6% in Operating Income Loss from 2024 to 2025.
- This data is from Whitehawk Therapeutics, Inc.'s annual report (Form 10-K), filed with the SEC on March 12, 2026.
- XBRL data for this metric is available from 2010 to 2025 (16 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Over the full 16 years of available data (2010 to 2025), Whitehawk Therapeutics, Inc.'s Operating Income Loss has declined by 557,703.9%.
- Historical annual values: Fiscal year 2025: -$114.40 million | Fiscal year 2024: -$67.46 million | Fiscal year 2023: -$71.93 million | Fiscal year 2022: -$62.68 million | Fiscal year 2021: -$111.22 million | Fiscal year 2020: -$2.55 million | Fiscal year 2019: -$24.44 million | Fiscal year 2018: -$11.18 million | Fiscal year 2017: -$21.39 million | Fiscal year 2016: -$16.63 million | Fiscal year 2015: -$23.0 thousand | Fiscal year 2014: -$24.0 thousand | Fiscal year 2013: -$22.8 thousand | Fiscal year 2012: -$22.4 thousand | Fiscal year 2011: -$23.6 thousand | Fiscal year 2010: -$20.5 thousand.
- Data sourced from SEC EDGAR public filings as of June 21, 2026.
Last verified: